Ball (BLL - Get Report) was upgraded to overweight from neutral at JPMorgan. $79 price target. The valuation is more attractive, as the Rexam deal makes both financial and strategic sense, JPMorgan said.
Bemis (BMS) was downgraded to market perform at BMO Capital. The valuation isn't as attractive, based on a $52 price target, BMO said.
Priceline (PCLN) was initiated with a sector weight rating at Pacific Crest.